vs
Side-by-side financial comparison of AVANOS MEDICAL, INC. (AVNS) and PARK NATIONAL CORP (PRK). Click either name above to swap in a different company.
AVANOS MEDICAL, INC. is the larger business by last-quarter revenue ($180.9M vs $168.3M, roughly 1.1× PARK NATIONAL CORP). PARK NATIONAL CORP runs the higher net margin — 25.3% vs -0.7%, a 26.1% gap on every dollar of revenue. On growth, PARK NATIONAL CORP posted the faster year-over-year revenue change (2.2% vs 0.7%). PARK NATIONAL CORP produced more free cash flow last quarter ($191.9M vs $21.3M). Over the past eight quarters, PARK NATIONAL CORP's revenue compounded faster (4.9% CAGR vs 4.4%).
Avanos Medical, Inc. is a medical technology company making clinical medical devices. The company consists of two franchises – Pain Management and Chronic Care – that address reducing the use of opioids while helping patients recover faster and preventing infection.
National Retail Systems, Inc. (NRS) includes Keystone Freight Corp. & National Retail Transportation, Inc. (NRT). NRS is an asset based 3PL founded in 1952. It is headquartered in Lyndhurst, New Jersey, United States.
AVNS vs PRK — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $180.9M | $168.3M |
| Net Profit | $-1.3M | $42.6M |
| Gross Margin | 47.5% | — |
| Operating Margin | 1.4% | — |
| Net Margin | -0.7% | 25.3% |
| Revenue YoY | 0.7% | 2.2% |
| Net Profit YoY | 99.7% | 10.4% |
| EPS (diluted) | $-0.02 | $2.62 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $180.9M | $168.3M | ||
| Q3 25 | $177.8M | $169.5M | ||
| Q2 25 | $175.0M | $168.7M | ||
| Q1 25 | $167.5M | $157.9M | ||
| Q4 24 | $179.6M | $164.7M | ||
| Q3 24 | $170.4M | $170.3M | ||
| Q2 24 | $171.7M | $157.7M | ||
| Q1 24 | $166.1M | $152.8M |
| Q4 25 | $-1.3M | $42.6M | ||
| Q3 25 | $-1.4M | $47.2M | ||
| Q2 25 | $-76.8M | $48.1M | ||
| Q1 25 | $6.6M | $42.2M | ||
| Q4 24 | $-397.3M | $38.6M | ||
| Q3 24 | $4.3M | $38.2M | ||
| Q2 24 | $1.8M | $39.4M | ||
| Q1 24 | $-900.0K | $35.2M |
| Q4 25 | 47.5% | — | ||
| Q3 25 | 48.4% | — | ||
| Q2 25 | 52.6% | — | ||
| Q1 25 | 53.6% | — | ||
| Q4 24 | 54.6% | — | ||
| Q3 24 | 54.5% | — | ||
| Q2 24 | 55.7% | — | ||
| Q1 24 | 57.1% | — |
| Q4 25 | 1.4% | — | ||
| Q3 25 | 0.1% | 34.3% | ||
| Q2 25 | -42.6% | 35.2% | ||
| Q1 25 | 6.1% | 32.4% | ||
| Q4 24 | -233.0% | — | ||
| Q3 24 | 7.0% | 27.4% | ||
| Q2 24 | 3.7% | 30.6% | ||
| Q1 24 | 2.4% | 27.8% |
| Q4 25 | -0.7% | 25.3% | ||
| Q3 25 | -0.8% | 27.8% | ||
| Q2 25 | -43.9% | 28.5% | ||
| Q1 25 | 3.9% | 26.7% | ||
| Q4 24 | -221.2% | 23.5% | ||
| Q3 24 | 2.5% | 22.4% | ||
| Q2 24 | 1.0% | 25.0% | ||
| Q1 24 | -0.5% | 23.0% |
| Q4 25 | $-0.02 | $2.62 | ||
| Q3 25 | $-0.03 | $2.92 | ||
| Q2 25 | $-1.66 | $2.97 | ||
| Q1 25 | $0.14 | $2.60 | ||
| Q4 24 | $-8.64 | $2.38 | ||
| Q3 24 | $0.09 | $2.35 | ||
| Q2 24 | $0.04 | $2.42 | ||
| Q1 24 | $-0.02 | $2.17 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $89.8M | $233.5M |
| Total DebtLower is stronger | $90.3M | — |
| Stockholders' EquityBook value | $778.2M | $1.4B |
| Total Assets | $1.1B | $9.8B |
| Debt / EquityLower = less leverage | 0.12× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $89.8M | $233.5M | ||
| Q3 25 | $70.5M | $218.9M | ||
| Q2 25 | $90.3M | $193.1M | ||
| Q1 25 | $97.0M | $237.6M | ||
| Q4 24 | $107.7M | $160.6M | ||
| Q3 24 | $89.0M | $201.7M | ||
| Q2 24 | $92.2M | $261.5M | ||
| Q1 24 | $75.8M | $306.1M |
| Q4 25 | $90.3M | — | ||
| Q3 25 | $93.4M | — | ||
| Q2 25 | $95.7M | — | ||
| Q1 25 | $98.0M | — | ||
| Q4 24 | $125.3M | — | ||
| Q3 24 | $152.6M | — | ||
| Q2 24 | $164.9M | — | ||
| Q1 24 | $167.2M | — |
| Q4 25 | $778.2M | $1.4B | ||
| Q3 25 | $778.0M | $1.3B | ||
| Q2 25 | $776.3M | $1.3B | ||
| Q1 25 | $839.4M | $1.3B | ||
| Q4 24 | $828.5M | $1.2B | ||
| Q3 24 | $1.2B | $1.2B | ||
| Q2 24 | $1.2B | $1.2B | ||
| Q1 24 | $1.2B | $1.2B |
| Q4 25 | $1.1B | $9.8B | ||
| Q3 25 | $1.1B | $9.9B | ||
| Q2 25 | $1.0B | $9.9B | ||
| Q1 25 | $1.1B | $9.9B | ||
| Q4 24 | $1.2B | $9.8B | ||
| Q3 24 | $1.7B | $9.9B | ||
| Q2 24 | $1.7B | $9.9B | ||
| Q1 24 | $1.7B | $9.9B |
| Q4 25 | 0.12× | — | ||
| Q3 25 | 0.12× | — | ||
| Q2 25 | 0.12× | — | ||
| Q1 25 | 0.12× | — | ||
| Q4 24 | 0.15× | — | ||
| Q3 24 | 0.12× | — | ||
| Q2 24 | 0.13× | — | ||
| Q1 24 | 0.14× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $28.2M | $198.3M |
| Free Cash FlowOCF − Capex | $21.3M | $191.9M |
| FCF MarginFCF / Revenue | 11.8% | 114.1% |
| Capex IntensityCapex / Revenue | 3.8% | 3.8% |
| Cash ConversionOCF / Net Profit | — | 4.65× |
| TTM Free Cash FlowTrailing 4 quarters | $43.1M | $328.2M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $28.2M | $198.3M | ||
| Q3 25 | $14.0M | $52.6M | ||
| Q2 25 | $6.8M | $49.7M | ||
| Q1 25 | $25.7M | $37.9M | ||
| Q4 24 | $57.9M | $178.8M | ||
| Q3 24 | $23.0M | $43.8M | ||
| Q2 24 | $27.8M | $50.9M | ||
| Q1 24 | $-8.0M | $35.0M |
| Q4 25 | $21.3M | $191.9M | ||
| Q3 25 | $7.0M | $51.1M | ||
| Q2 25 | $-4.2M | $48.4M | ||
| Q1 25 | $19.0M | $36.8M | ||
| Q4 24 | $53.1M | $169.7M | ||
| Q3 24 | $20.0M | $41.7M | ||
| Q2 24 | $21.9M | $49.0M | ||
| Q1 24 | $-12.1M | $31.9M |
| Q4 25 | 11.8% | 114.1% | ||
| Q3 25 | 3.9% | 30.1% | ||
| Q2 25 | -2.4% | 28.7% | ||
| Q1 25 | 11.3% | 23.3% | ||
| Q4 24 | 29.6% | 103.0% | ||
| Q3 24 | 11.7% | 24.5% | ||
| Q2 24 | 12.8% | 31.1% | ||
| Q1 24 | -7.3% | 20.8% |
| Q4 25 | 3.8% | 3.8% | ||
| Q3 25 | 3.9% | 0.9% | ||
| Q2 25 | 6.3% | 0.8% | ||
| Q1 25 | 4.0% | 0.7% | ||
| Q4 24 | 2.7% | 5.6% | ||
| Q3 24 | 1.8% | 1.2% | ||
| Q2 24 | 3.4% | 1.2% | ||
| Q1 24 | 2.5% | 2.1% |
| Q4 25 | — | 4.65× | ||
| Q3 25 | — | 1.11× | ||
| Q2 25 | — | 1.03× | ||
| Q1 25 | 3.89× | 0.90× | ||
| Q4 24 | — | 4.63× | ||
| Q3 24 | 5.35× | 1.14× | ||
| Q2 24 | 15.44× | 1.29× | ||
| Q1 24 | — | 0.99× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AVNS
| Enteral Feeding | $83.0M | 46% |
| Radiofrequency Ablation | $36.9M | 20% |
| Neonate Solutions | $32.1M | 18% |
| Surgical Pain And Recovery | $24.7M | 14% |
| Corporate Other | $4.2M | 2% |
PRK
Segment breakdown not available.
